<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIAZEPAM- diazepam injection, solution </strong><br>Hospira, Inc.<br></p></div>
<h1>DIAZEPAM Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="d8b5207e-8abc-4f2d-9b61-2d137027be3b"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">50 mg/10 mL</span></span></p>
<p><span class="Bold"><span class="Emphasis">(5 mg/mL)</span></span></p>
<p>Fliptop Vial</p>
<p><span class="Bold"><span class="Emphasis">CIV</span></span></p>
<p>Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="eecdac28-fffc-49f4-9945-4659d30d657c"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Diazepam Injection, USP is a sterile, nonpyrogenic solution intended for intramuscular or intravenous administration. Each milliliter (mL) contains 5 mg diazepam; 40% propylene glycol; 10% alcohol; 5% sodium benzoate and benzoic acid added as buffers; and 1.5% benzyl alcohol added as a preservative. pH 6.6 (6.2 to 6.9). Note: Solution may appear colorless to light yellow.</p>
<p>Diazepam is a benzodiazepine derivative chemically designated as 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. It is a colorless crystalline compound, insoluble in water, with the following molecular structure:</p>
<p><img alt="Diazepam Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0fb9bdfb-4d92-483e-acfe-4c9b2a84441c&amp;name=diazepam-nov-figure-1-3213N-SF.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ecb82bfd-b86f-4982-be5f-c061c3f0e5de"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">In animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with diazepam do have a transient <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> at higher doses. Diazepam was found to have transient cardiovascular depressor effects in dogs. Long-term experiments in rats revealed no disturbances of endocrine function. Injections into animals have produced localized irritation of tissue surrounding injection sites and some thickening of veins after intravenous use.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="a454c9e0-b0f2-4d5c-962c-f6915ba0e4e8"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Diazepam is indicated for the management of <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">anxiety disorders</span> or for the short-term relief of the symptoms of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>. <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> or <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> associated with the stress of everyday life usually does not require treatment with an anxiolytic.</p>
<p>In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, impending or <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">acute delirium</span> tremens and hallucinosis.</p>
<p>As an adjunct prior to endoscopic procedures if <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or acute stress reactions are present, and to diminish the patient’s recall of the procedures. (See <a href="#eb5be06b-6010-47b3-87e3-3fa847ac52de">WARNINGS</a>.)</p>
<p>Diazepam is a useful adjunct for the relief of skeletal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> due to reflex spasm to local pathology (such as <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the muscles or joints, or secondary to <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>); <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> caused by upper motor neuron disorders (such as <span class="product-label-link" type="condition" conceptid="4134120" conceptname="Cerebral palsy">cerebral palsy</span> and <span class="product-label-link" type="condition" conceptid="192606" conceptname="Paraplegia">paraplegia</span>); <span class="product-label-link" type="condition" conceptid="4259277" conceptname="Athetosis">athetosis</span>; stiff-man syndrome; and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>.</p>
<p>Diazepam is a useful adjunct in <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> and severe recurrent <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>.</p>
<p>Diazepam is a useful premedication (the I.M. route is preferred) for relief of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> and to diminish the patient’s recall of the procedure.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="cf56bf8c-1fe2-469c-934f-d06cd7d8cf1e"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Diazepam is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this drug; acute narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>; and <span class="product-label-link" type="condition" conceptid="435262" conceptname="Primary open angle glaucoma">open angle glaucoma</span> unless patients are receiving appropriate therapy.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="eb5be06b-6010-47b3-87e3-3fa847ac52de"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Italics"><span class="Emphasis">When used intravenously, the following procedures should be undertaken to reduce the possibility of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, local irritation, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and, rarely, vascular impairment; the solution should be injected slowly, taking at least one minute for each 5 mg (1 mL) given; do not use small veins, such as those on the dorsum of the hand or wrist; extreme care should be taken to avoid intra-arterial administration or <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.</span></span></p>
<p><span class="Italics"><span class="Emphasis">Do not mix or dilute diazepam with other solutions or drugs in syringe or infusion container. If it is not feasible to administer diazepam directly I.V., it may be injected slowly through the infusion tubing as close as possible to the vein insertion.</span></span></p>
<p>Extreme care must be used in administering Diazepam Injection, particularly by the I.V. route, to the elderly, to very ill patients and to those with limited pulmonary reserve because of the possibility that <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> and/or <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> may occur. Concomitant use of barbiturates, alcohol or other central nervous system depressants increases <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> with increased risk of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. Resuscitative equipment including that necessary to support respiration should be readily available.</p>
<p>When diazepam is used with a narcotic analgesic, the dosage of the narcotic should be reduced by at least one-third and administered in small increments. In some cases the use of a narcotic may not be necessary.</p>
<p>Diazepam Injection should not be administered to patients in <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, or in <span class="product-label-link" type="condition" conceptid="435140" conceptname="Toxic effect of alcohol">acute alcoholic intoxication</span> with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of vital signs. As is true of most CNS-acting drugs, patients receiving diazepam should be cautioned against engaging in hazardous occupations requiring complete mental alertness, such as operating machinery or driving a motor vehicle.</p>
<p>Tonic <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> has been precipitated in patients treated with I.V. diazepam for <span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span> status or <span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span> variant status.</p>
<p><span class="Bold"><span class="Emphasis">Usage in Pregnancy:</span></span></p>
<p><span class="Bold"><span class="Emphasis">An increased risk of congenital malformations associated with the use of minor tranquilizers (diazepam, meprobamate and chlordiazepoxide) during the first trimester of pregnancy has been suggested in several studies. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physicians about the desirability of discontinuing the drug.</span></span></p>
<p>In humans, measurable amounts of diazepam were found in maternal and cord blood, indicating placental transfer of the drug. Until additional information is available, diazepam injection is not recommended for obstetrical use.</p>
<p><span class="Bold"><span class="Emphasis">Pediatric Use:</span></span></p>
<p>Efficacy and safety of parenteral diazepam has not been established in the neonate (30 days or less of age).</p>
<p>Prolonged central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> has been observed in neonates, apparently due to inability to biotransform diazepam into inactive metabolites.</p>
<p>In pediatric use, in order to obtain maximal clinical effect with the minimum amount of drug and thus to reduce the risk of hazardous side effects, such as <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> or <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, it is recommended that the drug be given slowly over a three-minute period in a dosage not to exceed 0.25 mg/kg. After an interval of 15 to 30 minutes the initial dosage can be safely repeated. If, however, relief of symptoms is not obtained after a third administration, adjunctive therapy appropriate to the condition being treated is recommended.</p>
<p>Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines (see <a href="#e662d3da-3bf1-4938-8186-459a5096d22f">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a> section).</p>
<p>Benzyl alcohol has been reported to be associated with a fatal <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome in premature infants.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d2d32922-fb36-4c2a-aef3-f15debd548b2"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Although <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may be brought under control promptly, a significant proportion of patients experience a return to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity, presumably due to the short-lived effect of diazepam after I.V. administration. The physician should be prepared to re-administer the drug. However, diazepam is not recommended for maintenance, and once <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are brought under control, consideration should be given to the administration of agents useful in longer term control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>If diazepam is to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed—particularly with known compounds which may potentiate the action of diazepam, such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants. In highly anxious patients with evidence of accompanying <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, particularly those who may have suicidal tendencies, protective measures may be necessary. The usual precautions in treating patients with impaired hepatic function should be observed. Metabolites of diazepam are excreted by the kidney; to avoid their excess accumulation, caution should be exercised in the administration to patients with compromised kidney function.</p>
<p>Since an increase in <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex and <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> may occur with peroral endoscopic procedures, the use of a topical anesthetic agent and the availability of necessary countermeasures are recommended.</p>
<p>Propylene glycol toxicity has been reported in patients treated with diazepam injection at doses significantly greater than recommended. In these cases, diazepam was being used to treat alcohol withdrawal symptoms at doses greater than 900 mg/day. Propylene glycol toxicity is associated with an <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span> <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, serum hyperosmolality, and increased lactate. Propylene glycol toxicity can cause <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">acute tubular necrosis</span> (which can progress to multi-organ failure), <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. Patients at high risk for propylene glycol toxicity include those with renal dysfunction, hepatic dysfunction, impaired alcohol dehydrogenase enzymes, or other comorbidities (such as a history of <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>).</p>
<p>Until additional information is available, diazepam injection is not recommended for obstetrical use.</p>
<p>Diazepam injection has produced <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> in some patients particularly when used with narcotics, barbiturates or alcohol. Lower doses (usually 2 mg to 5 mg) should be used for elderly and debilitated patients.</p>
<p>The clearance of diazepam and certain other benzodiazepines can be delayed in association with cimetidine administration. The clinical significance of this is unclear.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="baa9e15b-2a7a-472f-a3d0-a12dea47c930"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Side effects most commonly reported were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>; <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> at the site of injection. Other adverse reactions less frequently reported include: <span class="Italics"><span class="Emphasis">CNS: </span></span><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. <span class="Italics"><span class="Emphasis">G.I.:</span></span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. <span class="Italics"><span class="Emphasis">G.U.:</span></span> <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, changes in libido, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. <span class="Italics"><span class="Emphasis">Cardiovascular</span></span>: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. <span class="Italics"><span class="Emphasis">EENT:</span></span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>. <span class="Italics"><span class="Emphasis">Skin:</span></span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. <span class="Italics"><span class="Emphasis">Other:</span></span> <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, changes in <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. Paradoxical reactions such as acute hyperexcited states, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, increased <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">muscle spasticity</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">rage</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span> and stimulation have been reported; should these occur, use of the drug should be discontinued. Minor changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after diazepam therapy and are of no known significance.</p>
<p>In peroral endoscopic procedures, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, depressed respiration, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in throat or chest have been reported.</p>
<p>Because of isolated reports of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, periodic blood counts and liver function tests are advisable during long-term therapy.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="e662d3da-3bf1-4938-8186-459a5096d22f"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Diazepam Injection is classified by the Drug Enforcement Administration as a schedule IV controlled substance.</p>
<p>Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, abdominal and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>), have occurred following abrupt discontinuance of diazepam. The more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving diazepam or other psychotropic agents because of the predisposition of such patients to <span class="product-label-link" type="condition" conceptid="4036424" conceptname="Drug tolerance">habituation</span> and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="edf96a11-f12f-43f2-a1e6-4d6dffd363e0"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage should be individualized for maximum beneficial effect. The usual recommended dose in older children and adults ranges from 2 mg to 20 mg I.M. or I.V., depending on the indication and its severity. In some conditions, e.g., <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, larger doses may be required. (See dosage for specific indications.) In acute conditions the injection may be repeated within one hour although an interval of 3 to 4 hours is usually satisfactory. Lower doses (usually 2 mg to 5 mg) and slow increase in dosage should be used for elderly or debilitated patients and when other sedative drugs are administered. (See <a href="#eb5be06b-6010-47b3-87e3-3fa847ac52de">WARNINGS</a> and <a href="#baa9e15b-2a7a-472f-a3d0-a12dea47c930">ADVERSE REACTIONS</a>.)</p>
<p>For dosage in infants above the age of 30 days and children, see the specific indications below. When intravenous use is indicated, facilities for respiratory assistance should be readily available.</p>
<p><span class="Italics"><span class="Emphasis">Intramuscular:</span></span> Diazepam Injection, USP should be injected deeply into the muscle.</p>
<p><span class="Italics"><span class="Emphasis">Intravenous use:</span></span> (See <a href="#eb5be06b-6010-47b3-87e3-3fa847ac52de">WARNINGS</a>, particularly for use in children.) The solution should be injected slowly, taking at least one minute for each 5 mg (1 mL) given. Do not use small veins, such as those on the dorsum of the hand or wrist. Extreme care should be taken to avoid intra-arterial administration or <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.</p>
<p>Do not mix or dilute diazepam with other solutions or drugs in syringe or infusion flask. If it is not feasible to administer diazepam directly I.V., it may be injected slowly through the infusion tubing as close as possible to the vein insertion.</p>
<p>Once the acute symptomatology has been properly controlled with diazepam injection, the patient may be placed on oral therapy with diazepam if further treatment is required.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit (see <a href="#d2d32922-fb36-4c2a-aef3-f15debd548b2">PRECAUTIONS</a>). NOTE: Solution may appear colorless to light yellow. </p>
<table width=" 97.68%"><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">USUAL ADULT</span></span></p>
<p><span class="Bold"><span class="Emphasis">DOSAGE</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">DOSAGE RANGE</span></span></p>
<p><span class="Bold"><span class="Emphasis">IN CHILDREN</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">(I.V. administration should be made slowly)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Moderate <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">Anxiety Disorders</span> and Symptoms of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 mg to 5 mg, I.M. or I.V. Repeat in 3 to 4 hours, if necessary.</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Severe <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">Anxiety Disorders</span> and Symptoms of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 mg to 10 mg, I.M. or I.V. Repeat in 3 to 4 hours, if necessary.</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Acute Alcohol Withdrawal:</span></span> As an aid in symptomatic relief of acute <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, impending or <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">acute delirium</span> tremens and hallucinosis.</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">10 mg, I.M. or I.V. initially, then 5 mg to 10 mg in 3 to 4 hours, if necessary.</p>
<p> </p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Endoscopic Procedures:</span></span> Adjunctively, if <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or acute stress reactions are present prior to endoscopic procedures. Dosage of narcotics should be reduced by at least a third and in some cases may be omitted. See <span class="Italics"><span class="Emphasis">Precautions</span></span> for peroral procedures.</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Titrate I.V. dosage to desired sedative response, such as slurring of speech, with slow administration immediately prior to the procedure. Generally 10 mg or less is adequate, but up to 20 mg I.V. may be given, particularly when concomitant narcotics are omitted. If I.V. cannot be used, 5 mg to 10 mg I.M. approximately 30 minutes prior to the procedure.</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Spasm</span>:</span></span> Associated with local pathology, <span class="product-label-link" type="condition" conceptid="4134120" conceptname="Cerebral palsy">cerebral palsy</span>, <span class="product-label-link" type="condition" conceptid="4259277" conceptname="Athetosis">athetosis</span>, stiff-man syndrome or <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>.</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 mg to 10 mg, I.M. or I.V. initially, then 5 mg to 10 mg in 3 to 4 hours, if necessary. For <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, larger doses may be required.</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">For <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> in infants over 30 days of age, 1 mg to 2 mg I.M. or I.V., slowly, repeated every 3 to 4 hours as necessary. In children 5 years or older, 5 mg to 10 mg repeated every 3 to 4 hours may be required to control <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>. Respiratory assistance should be available.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">Status Epilepticus</span> and Severe Recurrent <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive Seizures</span>:</span></span> In the convulsing patient, the I.V. route is by far preferred. This injection should be administered slowly. However, if I.V. administration is impossible, the I.M. route may be used.</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">5 mg to 10 mg initially (I.V. preferred). This injection may be repeated if necessary at 10 to 15 minute intervals up to a maximum dose of 30 mg.</p>
<p>If necessary, therapy with diazepam may be repeated in 2 to 4 hours; however, residual active metabolites may persist, and readministration should be made with this consideration.</p>
<p>Extreme caution must be exercised with individuals with chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> or unstable cardiovascular status.</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Infants over 30 days of age and children under 5 years, 0.2 mg to 0.5 mg slowly every 2 to 5 minutes up to a maximum of 5 mg (I.V. preferred). Children 5 years or older, 1 mg every 2 to 5 minutes up to a maximum of 10 mg (slow I.V. administration preferred). Repeat in 2 to 4 hours if necessary. EEG monitoring of the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> may be helpful. </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Preoperative Medication:</span></span> To relieve <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>. (If atropine, scopolamine or other premedications are desired, they must be administered in separate syringes.)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">10 mg, I.M. (preferred route), before surgery. </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Italics"><span class="Emphasis">Cardioversion:</span></span> To relieve <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> and to reduce recall of procedure. </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 mg to 15 mg, I.V., within 5 to 10 minutes prior to the procedure.</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
</tr>
</tbody></table>
<p><span class="Bold"><span class="Emphasis"><span class="Italics">MANAGEMENT OF OVERDOSAGE</span></span></span></p>
<p><span class="Bold"><span class="Emphasis">Manifestations of diazepam overdosage include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">diminished reflexes</span>. Respiration, pulse and blood pressure should be monitored, as in all cases of drug overdosage, although, in general, these effects have been minimal. General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value.</span></span></p>
<p>Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation, and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Patients treated with flumazenil should be monitored for re-sedation, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and other residual benzodiazepine effects for an appropriate period after treatment. <span class="Bold"><span class="Emphasis">The prescriber should be aware of a risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </span></span>The complete flumazenil package insert including <span class="Bold"><span class="Emphasis"><a href="#cf56bf8c-1fe2-469c-934f-d06cd7d8cf1e">CONTRAINDICATIONS</a></span></span>, <span class="Bold"><span class="Emphasis"><a href="#eb5be06b-6010-47b3-87e3-3fa847ac52de">WARNINGS</a></span></span>, and <span class="Bold"><span class="Emphasis"><a href="#d2d32922-fb36-4c2a-aef3-f15debd548b2">PRECAUTIONS</a></span></span> should be consulted prior to use.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="a9bb3896-27c1-42cf-ac4b-61ed82b8d4a2"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Diazepam Injection, USP is supplied as follows:</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Unit of Sale</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Concentration</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Each</span></span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC 0409-3213-10</span></span></p>
<p>Carton containing 10</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">50 mg/10 mL</p>
<p>(5 mg/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">NDC 0409-3213-09</p>
<p>10 mL multiple dose vial</p>
</td>
</tr>
</tbody></table>
<p>Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] </p>
<p><span class="Bold"><span class="Emphasis">Protect from light.</span></span></p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="a279477b-ca66-448f-a032-b4b84952efa7"></a><a name="section-12"></a><p></p>
<h1>ANIMAL PHARMACOLOGY</h1>
<p class="First">Oral LD<span class="Sub">50</span> of diazepam is 720 mg/kg in mice and 1240 mg/kg in rats. Intraperitoneal administration of 400 mg/kg to a monkey resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> on the sixth day.</p>
<p><span class="Italics"><span class="Emphasis">Reproduction Studies:</span></span> A series of rat reproduction studies was performed with diazepam in oral doses of 1, 10, 80 and 100 mg/kg given for periods ranging from 60–228 days prior to mating. At 100 mg/kg there was a decrease in the number of pregnancies and surviving offspring in these rats. These effects may be attributable to prolonged sedative activity, resulting in lack of interest in mating and lessened maternal nursing and care of the young. Neonatal survival of rats at doses lower than 100 mg/kg was within normal limits. Several neonates, both controls and experimentals, in these rat reproduction studies showed skeletal or other defects. Further studies in rats at doses up to and including 80 mg/kg/day did not reveal significant teratological effects on the offspring. Rabbits were maintained on doses of 1, 2, 5 and 8 mg/kg from day 6 through day 18 of gestation. No adverse effects on reproduction and no teratological changes were noted.</p>
<p>Revised: 2/2014</p>
<p> </p>
<p>                                                                                                 EN-3480 </p>
<p>Manufactured by Hospira, Inc., Lake Forest, IL 60045 USA</p>
<p> </p>
<p>NOVAPLUS is a registered trademark of Novation, LLC.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="bebb7404-cc9d-4783-b692-903abea85757"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">CA-3256 (Front)</span></span></p>
<p><span class="Bold"><span class="Emphasis"><img alt="Carton NDC 0409-3213-10 (Front)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0fb9bdfb-4d92-483e-acfe-4c9b2a84441c&amp;name=diazepam-nov-figure-2-jCA-3256-F.jpg"></span></span></p>
<p><span class="Bold"><span class="Emphasis">CA-3256 (Back</span></span>)</p>
<p><img alt="Carton NDC 0409-3213-10 (Back)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0fb9bdfb-4d92-483e-acfe-4c9b2a84441c&amp;name=diazepam-nov-figure-3-jCA-3256-B.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIAZEPAM 		
					</strong><br><span class="contentTableReg">diazepam injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-3213</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIAZEPAM</strong> (DIAZEPAM) </td>
<td class="formItem">DIAZEPAM</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">0.4 mL  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">0.1 mL  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">0.015 mL  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZOIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-3213-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-3213-09</td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA071583</td>
<td class="formItem">10/13/1987</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Hospira, Inc.
							(141588017)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0d44b53d-1a51-42a2-8b7c-f6c4e3ee2a4f</div>
<div>Set id: 0fb9bdfb-4d92-483e-acfe-4c9b2a84441c</div>
<div>Version: 1</div>
<div>Effective Time: 20140520</div>
</div>
</div> <div class="DistributorName">Hospira, Inc.</div></p>
</body></html>
